廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8252
    -0.0005 (-0.01%)
     
  • 人民幣

    0.9222
    -0.0006 (-0.07%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0000 (+0.02%)
     
  • 歐元

    8.4424
    +0.0019 (+0.02%)
     
  • 英鎊

    9.8690
    -0.0070 (-0.07%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    70,300.20
    -396.54 (-0.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Verve Therapeutics Posts Updated Preclinical Data For Gene-Editing Therapy In Cardiovascular Disease

  • Verve Therapeutics Inc (NASDAQ: VERV) announced new preclinical data supporting the nomination of the company's second product candidate, VERVE-201.

  • VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism.

  • Verve is initially developing VERVE-201 for homozygous familial hypercholesterolemia (HoFH), a rare genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood low-density lipoprotein cholesterol (LDL-C).

  • Also Read: Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program.

  • The preclinical studies showed potent, on-target editing of the ANGPTL3 gene with no detectable off-target and no detectable structural variants as assessed using high-coverage whole genome optical mapping.

  • Verve also conducted a non-human primate (NHP) study (n=9) demonstrating potent liver ANGPTL3 editing of 54-57% and reductions in blood ANGPTL3 protein of 95-98% across three dose levels.

  • Additionally, Verve shared an update on previously reported data with an ANGPTL3 precursor formulation targeting the same base editing outcome in NHPs.

  • These data demonstrated durable editing in the liver of treated NHPs (n=4) of 61% over two years following dosing, which was identical to editing levels measured via a liver biopsy on day 15.

  • Price Action: VERV shares are up 3.17% at $34.54 on the last check Monday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.